Olpha has a long-term strategy to expand portfolio and develop sustainable business in different territories. It is a continuous process — new products are constantly being evaluated and included in the portfolio.
Contact usFor successful partnering we ensure reliable communication and high level supporting. To expand your product line or enter new markets, Olpha will find the best option to achieve your goals. Our partners already covers key regions, including the EU, CIS, Southeast Asia, Africa and the Middle East.
production
production capacity for
tablets and capsules per year
investment in
R&D in 2022
investment in new generic medicine portfolio in 2024
With a team of 850+ professional employees and 50+ years of experience, Olpha is an expert in the development and production of finished dosage forms and active pharmaceutical ingredients and intermediates in a vast range of therapeutic areas.
Our production plant is located in the European Union, in Latvia, and has a 480,000 square meter area with easy access to the highway and airport. Our laboratories are equipped with modern, industry standard instruments.
We approach each client’s needs and evaluate each cooperation on an individual level. We believe the best way of collaborating is finding the most suitable solution for any need together.
Olpha is develops generics as well as APIs and
stands out with the full-cycle production offering.
Olpha ensures consistent product availability to meet
the market demand.
Efficient production processes, lower labour costs and regionally
developed logistics result in greater cost efficiency.
Olpha holds its production to the highest industry quality standards.
See more information on quality control and assurance on our
Product governance page.
Our processes include effective sustainability measures, ensuring
that our business processes are good for people and the planet.
See more information on our Sustainability section.